Samsung Biology said Samsung BioLogics Today, Tuesday, it is producing large quantities of anti-corona virus treatments developed by Eli Lilly Eli LillyThe United States began distributing the drug last week after approval for emergency use.
Eli Lilly said that the FDA ” FDAI approved bamalivimab bamlanivimab Earlier this month, after clinical trials showed that it reduced the need for hospitalization, or emergency room visits, for coronavirus patients who are at high risk of developing the matter, according to Eli Lilly.
On the other hand, the American Authority said, ” FDAThe drug may be used for people over the age of 65 who have recently been diagnosed Coronavirus Mild to moderate, and those over the age of 12 with underlying health conditions that put them at risk of developing serious complications.
Night aiming Lilly To manufacture up to 1 million doses by the end of 2020, for use around the world until early next year, and expects to significantly increase supply from the first quarter of 2021 as additional manufacturing resources emerge online..
Company said Samsung Biology It has a long-term manufacturing contract with Lilly, and has not disclosed details.
The South Korean company said that it initially struggled to secure raw materials due to a lack of supplies. The technology transfer process has accelerated, allowing it to begin shipments to Lilly. Lilly 5 months after the production deal was approved in May.
According to Eli Lilly, the drug is a monoclonal antibody, a widely used class of biotechnology drugs, and is a synthetic version of an antibody made by the human body to fight infection..
Other potential antibody therapies being developed for coronavirus patients include one by the U.S. patent, the drug company Regeneron. Regeneron, Which President Donald Trump received after his diagnosis last month.
These were the details of the news Samsung Biologics produces one million doses of the Corona drug by... for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at saudi24news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
